A bipartisan group in the US congress is looking to pass a bill to limit the Centers for Medicare and Medicaid Services (CMS) from lumping in all amyloid-targeted drugs with the controversial Alzheimer's drug Aduhelm. The move comes as two new amyloid-targeted therapies have shown promising results in slowing cognitive decline.
According to Rep. Vern Buchanan (R-FL), “With additional drugs to treat Alzheimer's preparing to come to market soon, this bill will ensure those drugs receive fair and accurate consideration for coverage, rather than requiring onerous additional steps before CMS will make them available to Medicare beneficiaries”
To read more, click here.
(Source: Endpoints News, October 5th, 2022)